VRAXHealthcare · BiotechnologyThe 1 Wall Street analysts covering Virax Biolabs Group Ltd. hold a median 12-month price target of $25 — +1983.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 4 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Virax Biolabs Group Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Value (6): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on VRAX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1983.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | $3.00 → $1.00 |
| 31 Mar 2025 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VRAX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Virax Biolabs Group Ltd. returned −90.6% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 77% of US stocks
Cheaper than 3% of US stocks
Cheaper than 90% of US stocks
Cheaper than 58% of US stocks
Higher than 98% of US stocks
Higher than 1% of US stocks
Higher than 97% of US stocks
Higher than 16% of US stocks
Higher than 7% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Virax Biolabs Group Ltd. has a market value of $1.6M and an enterprise value of −$5.7M.
Trailing P/E: −0.1×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Virax Biolabs Group Ltd. employs 26 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Virax Biolabs Group Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Virax Biolabs said its China subsidiary entered non-exclusive distribution agreements with AmyJet Scientific and Jiangsu Real-Gen Biotechnology for ImmuneSelect research products, building on initial China sales.
Why it matters — The agreements extend VRAX's distributor-led commercial strategy in mainland China.
The 1 Wall Street analysts covering Virax Biolabs Group Ltd. have a median 12-month price target of $25, with estimates ranging from $25 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Virax Biolabs Group Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Virax Biolabs Group Ltd. 15 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Virax Biolabs Group Ltd. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +1983.3% from the last close, and Ticker Nerd's factor model ranks Virax Biolabs Group Ltd. 15 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Virax Biolabs Group Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $25 over the next 12 months.
Virax Biolabs Group Ltd. returned -90.6% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Virax Biolabs Group Ltd. is a biotechnology company focused on immune response detection and the diagnosis of viral diseases.
The most recent item we track (PRNewsWire, 29 Oct 2026): "Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China". Virax Biolabs said its China subsidiary entered non-exclusive distribution agreements with AmyJet Scientific and Jiangsu Real-Gen Biotechnology for ImmuneSelect research products, building on initial China sales.
Virax Biolabs Group Ltd. is a biotechnology company focused on immune response detection and the diagnosis of viral diseases. Its core work centers on T cell-based in vitro diagnostic technologies and immunology profiling tools designed to help assess immune risk related to viral and immune-mediated conditions. The company develops and commercializes diagnostic test kits and related med-tech products under the ViraxClear brand, while its ViraxImmune platform is intended to support immune profiling and the evaluation of post-viral syndromes such as Long COVID and other chronic immune dysfunction states. Virax Biolabs Group Ltd. serves healthcare and research-oriented markets where viral detection, immune assessment, and diagnostic support are important, positioning the company within the broader biotechnology and in vitro diagnostics sectors. The company is headquartered in BioCity Glasgow, United Kingdom.
CEO Mr. James Foster · 26 employees · United Kingdom · https://viraxbiolabs.com
